HOUSTON, Texas — Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis (IPF)....
Latest News
One year ago, an Idaho Falls couple was shocked to hear doctors say their twin boys were dying from a rare disease that eats at the muscle. Friends and family want to make sure that for however long the Devereaux boys live, their lives are full of joy and comfort....
Toronto, Ontario – The Global Alliance for Genomics and Health (GA4GH) and the International Neuroinformatics Coordinating Facility (INCF) launched a new group to lay the groundwork for connecting global neuroscience and genomic data. Answering data-driven questions in neuroscience means dealing with complexity: in types of data, data management systems, the...
BOSTON, Mass. – GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. “Before this study, there...
COLUMBUS, Ohio – Two five-year grants totaling more than $6 million from the National Cancer Institute (NCI) will help The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) researchers and colleagues at other institutions better understand acute...
PARIS — Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB. The antibiotic levofloxacin safely reduced the risk of multidrug-resistant (MDR) tuberculosis (TB) disease in children by 56%, researchers from the...
Pittsburgh, PA – Two studies published in the latest issue of the journal Cell by University of Pittsburgh researchers uncover how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses. The findings shed light on why combination therapies targeting both checkpoints can improve outcomes for...
Bochum, Germany – A research team from the Department of Medical and Molecular Virology at Ruhr University Bochum monitored and treated two patients with chronic hepatitis E with a combination of sofosbuvir and ribavirin after they had not previously responded to ribavirin alone. “In both cases, the combination therapy was...
Stockholm, Sweden – There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska Institutet. Both forms of treatment produced a significant reduction in symptoms in people affected by the disease....
Recall the saying “there are a thousand ways to skin a cat”? Researchers are rephrasing it in regard to the mosquito. Fifty years ago, we thought that the war against malaria was pretty much won. We had quinine and chloroquine, which were effective against the parasite that causes the disease....